Clinical Trial Update: Shigella Sonnei OSPC-rDT Conjugate Vaccine [Phase 1]

View source ↗

Summary

A Phase 1 trial of the Shigella Sonnei OSPC-rDT Conjugate Vaccine has been withdrawn from the study registry.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Shigellosis

Drugs mentioned

• Shigella Sonnei OSPC-rDT Conjugate Vaccine

Snippet

Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Conditions: Shigellosis | Phase 1 | Status: WITHDRAWN